[go: up one dir, main page]

MA32161B1 - Formes de rifaximine et utilisations de celles-ci - Google Patents

Formes de rifaximine et utilisations de celles-ci

Info

Publication number
MA32161B1
MA32161B1 MA33179A MA33179A MA32161B1 MA 32161 B1 MA32161 B1 MA 32161B1 MA 33179 A MA33179 A MA 33179A MA 33179 A MA33179 A MA 33179A MA 32161 B1 MA32161 B1 MA 32161B1
Authority
MA
Morocco
Prior art keywords
rifaximin forms
rifaximin
forms
rifamixin
hydrates
Prior art date
Application number
MA33179A
Other languages
Arabic (ar)
English (en)
Inventor
Donglai Yang
Melanie Roe
Karen S Gushurst
Nathan Schultheiss
Petinka Vlahova
Jeffrey S Stults
Travis L Houston
Original Assignee
Salix Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41016698&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA32161(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Salix Pharmaceuticals Ltd filed Critical Salix Pharmaceuticals Ltd
Publication of MA32161B1 publication Critical patent/MA32161B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La présente invention concerne les formes polymorphes, salines, hydrates et amorphes de la rifaximine, leur utilisation dans des préparations médicinales, et des procédés thérapeutiques les utilisant.
MA33179A 2008-02-25 2010-09-13 Formes de rifaximine et utilisations de celles-ci MA32161B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3132908P 2008-02-25 2008-02-25
PCT/US2009/035192 WO2009108730A2 (fr) 2008-02-25 2009-02-25 Formes de rifaximine et utilisations correspondantes

Publications (1)

Publication Number Publication Date
MA32161B1 true MA32161B1 (fr) 2011-03-01

Family

ID=41016698

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33179A MA32161B1 (fr) 2008-02-25 2010-09-13 Formes de rifaximine et utilisations de celles-ci

Country Status (21)

Country Link
US (7) US8067429B2 (fr)
EP (1) EP2257557A4 (fr)
JP (2) JP5706693B2 (fr)
KR (1) KR101674382B1 (fr)
CN (2) CN104650114A (fr)
AU (1) AU2009219342B2 (fr)
BR (1) BRPI0908864A2 (fr)
CA (1) CA2716830C (fr)
CR (2) CR11657A (fr)
EA (2) EA201370208A1 (fr)
GE (1) GEP20135898B (fr)
IL (1) IL207730A (fr)
MA (1) MA32161B1 (fr)
ME (1) ME01032B (fr)
MX (2) MX344737B (fr)
MY (1) MY158257A (fr)
NZ (1) NZ587099A (fr)
SG (2) SG188931A1 (fr)
UA (2) UA101829C2 (fr)
WO (1) WO2009108730A2 (fr)
ZA (2) ZA201005961B (fr)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7923553B2 (en) 2003-11-07 2011-04-12 Alfa Wassermann, S.P.A. Processes for the production of polymorphic forms of rifaximin
US7902206B2 (en) 2003-11-07 2011-03-08 Alfa Wassermann, S.P.A. Polymorphic forms α, β and γ of rifaximin
ITMI20032144A1 (it) 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e
US7906542B2 (en) 2004-11-04 2011-03-15 Alfa Wassermann, S.P.A. Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin
PL1698630T3 (pl) 2005-03-03 2014-12-31 Alfasigma Spa Nowe postacie polimorficzne rifaksyminy,sposoby ich wytwarzania i ich zastosowanie w preparatach leczniczych
EP2257557A4 (fr) 2008-02-25 2011-06-29 Salix Pharmaceuticals Ltd Formes de rifaximine et utilisations correspondantes
US8486956B2 (en) * 2008-02-25 2013-07-16 Salix Pharmaceuticals, Ltd Forms of rifaximin and uses thereof
US11779571B2 (en) 2008-02-26 2023-10-10 Salix Pharmaceuticals, Inc. Methods for treating irritable bowel syndrome (IBS)
US20110035232A1 (en) 2008-10-02 2011-02-10 Salix Pharmaceuticals, Ltd. Methods of treating hepatic encephalopathy
US7928115B2 (en) * 2008-10-02 2011-04-19 Salix Pharmaceuticals, Ltd. Methods of treating travelers diarrhea and hepatic encephalopathy
ES2770308T3 (es) 2008-10-02 2020-07-01 Salix Pharmaceuticals Ltd Procedimientos de tratamiento de encefalopatía hepática
US12285414B2 (en) 2008-10-02 2025-04-29 Salix Pharmaceuticals, Inc. Methods of treating hepatic encephalopathy
US9018684B2 (en) 2009-11-23 2015-04-28 California Institute Of Technology Chemical sensing and/or measuring devices and methods
US8952159B2 (en) 2009-12-28 2015-02-10 Silvio Massimo Lavagna Method for the production of amorphous rifaximin
IT1399141B1 (it) * 2010-04-02 2013-04-05 Secci Metodo per la preparazione di rifaximina in stato amorfo.
IT1397107B1 (it) * 2009-12-28 2012-12-28 Lavagna Nuovo metodo per la preparazione di antibiotici in stato amorfo e prodotti ottenuti utilizzando detto metodo.
IT1398550B1 (it) * 2010-03-05 2013-03-01 Alfa Wassermann Spa Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo
AU2015203018B2 (en) * 2010-06-03 2016-10-20 Salix Pharmaceuticals, Ltd. New forms of rifaximin and uses thereof
EA022490B1 (ru) * 2010-06-03 2016-01-29 Саликс Фармасьютикалс, Лтд. Новые формы рифаксимина и их применение
CA2802874A1 (fr) * 2010-06-16 2011-12-22 Apotex Pharmachem Inc. Formes polymorphiques de rifaximine
GEAP202112996A (en) * 2010-07-12 2021-09-10 Salix Pharmaceuticals Ltd Us Formulations of rifaximin and uses thereof
US8759513B2 (en) 2010-09-13 2014-06-24 Sequent Scientific Limited Polymorphic form of rifaximin and process for its preparation
IT1403847B1 (it) 2010-09-22 2013-11-08 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina e loro uso.
KR20140026379A (ko) * 2011-02-11 2014-03-05 샐릭스 파마슈티컬스 리미티드 리팍시민의 형태 및 이의 용도
CA2834829A1 (fr) 2011-05-02 2012-11-08 Ranbaxy Laboratories Limited Solvate de dimethylformamide rifaximine
WO2012155981A1 (fr) 2011-05-19 2012-11-22 Friulchem Spa Nouveau procédé pour la synthèse de rifaximine et nouvelle forme pseudo-cristalline de rifaximine obtenue au moyen de celui-ci
ITMI20110890A1 (it) 2011-05-19 2012-11-20 A M S A Anonima Materie Sint & Affini S P A Polimorfo di rifaximina e processo per la sua preparazione
ITMI20110983A1 (it) * 2011-05-30 2012-12-01 A M S A Anonima Materie Sint & Affini S P A Amorfo di rifaximina e processo per la sua preparazione
WO2013027227A1 (fr) * 2011-07-20 2013-02-28 Ind-Swift Laboratories Limited Nouvelle forme polymorphe i de la rifaximine
ITBO20110461A1 (it) 2011-07-29 2013-01-30 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali.
ES2986825T3 (es) * 2011-11-02 2024-11-12 Salix Pharmaceuticals Inc Rifaximina para la repetición de tratamiento del síndrome del intestino irritable con predominio de diarrea
WO2013112809A2 (fr) 2012-01-25 2013-08-01 Salix Pharmaceuticals, Ltd Dérivé de rifaximine et ses utilisations
JP2013184902A (ja) * 2012-03-06 2013-09-19 Aska Pharmaceutical Co Ltd リファキシミン含有結晶
WO2013185211A1 (fr) * 2012-06-13 2013-12-19 Apotex Pharmachem Inc. Formes polymorphes de rifaximine
ITBO20120368A1 (it) * 2012-07-06 2014-01-07 Alfa Wassermann Spa Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso.
US9849090B2 (en) 2012-12-12 2017-12-26 Sun Pharmaceutical Industries Limited Pharmaceutical compositions of rifaximin
EP2971062A2 (fr) 2013-03-15 2016-01-20 ALFA WASSERMANN S.p.A. Procédé pour diagnostiquer des infections vaginales
US20160038468A1 (en) 2013-03-15 2016-02-11 Alfa Wassermann S.P.A. Rifaximin for use in the treating of vaginal infections
CA2908525C (fr) 2013-04-12 2021-04-06 Alfa Wassermann S.P.A. Administration d'ains, compositions, procedes et systemes associes
ITMI20131307A1 (it) * 2013-08-02 2015-02-02 A M S A Anonima Materie Sint & Affini S P A Processo per la preparazione di refaximina k
CN103509038B (zh) * 2013-09-30 2016-01-20 浙江思贤制药有限公司 一种新晶型利福昔明ζ及其制备方法
EP2927235B1 (fr) 2014-03-31 2017-02-08 Euticals S.P.A. Mélange de polymorphes de rifaximine et son utilisation pour la préparation de formulations solides
MX375805B (es) * 2014-05-04 2025-03-07 Salix Pharmaceuticals Inc Microbiota ibs y sus usos.
JP6576953B2 (ja) 2014-05-12 2019-09-18 アルファシグマ ソシエタ ペル アチオニ リファキシミンの新規溶媒和物結晶形、生成物、組成物及びそれらの使用
WO2016003536A1 (fr) * 2014-06-30 2016-01-07 Salix Pharmaceuticals, Inc. Procédés pour le retraitement du syndrome du côlon irritable
US9988398B2 (en) 2016-06-07 2018-06-05 Cadila Healthcare Limited Crystalline form of rifaximin and process for its preparation
EP3518924B1 (fr) 2016-09-30 2022-08-10 Salix Pharmaceuticals, Inc. Formes de dispersions solides de rifaximine
CN106632396B (zh) * 2017-01-06 2019-01-11 成都樵枫科技发展有限公司 γ晶型利福昔明的制备方法和用途
US10143656B1 (en) 2017-08-04 2018-12-04 Braintree Laboratories, Inc. Solid oral sulfate salt formulations for cleaning a colon and methods of using same
WO2020128583A1 (fr) * 2018-12-19 2020-06-25 Friulchem S.P.A. Procédé de fabrication d'un comprimé de rifaximine et comprimé de rifaximine
US12239659B2 (en) 2023-06-15 2025-03-04 Braintree Laboratories, Inc. Methods of administering safe colon cleansing compositions

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1154655B (it) * 1980-05-22 1987-01-21 Alfa Farmaceutici Spa Derivati imidazo-rifamicinici metodi per la loro preparazione e loro uso come sostanza ad azione antibatterica
IT1199374B (it) * 1984-05-15 1988-12-30 Alfa Farmaceutici Spa Processo per la preparazione di pirido-imidazo-rifamicine
CA2396079A1 (fr) 2000-01-07 2001-07-19 Transform Pharmaceuticals, Inc. Formation, identification et analyse a productivites elevees de formes solides diverses
ITMI20032144A1 (it) * 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e
US7902206B2 (en) * 2003-11-07 2011-03-08 Alfa Wassermann, S.P.A. Polymorphic forms α, β and γ of rifaximin
US7906542B2 (en) 2004-11-04 2011-03-15 Alfa Wassermann, S.P.A. Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin
US20080262024A1 (en) * 2003-11-07 2008-10-23 Giuseppe Claudio Viscomi Rifaximin compositions and method of use
US7923553B2 (en) 2003-11-07 2011-04-12 Alfa Wassermann, S.P.A. Processes for the production of polymorphic forms of rifaximin
US7226931B2 (en) 2004-07-22 2007-06-05 Cumbre Pharmaceuticals Inc. (R/S) rifamycin derivatives, their preparations and pharmaceutical compositions
US8003118B2 (en) * 2005-03-02 2011-08-23 Kodsi Robert E Use of rifaximin for the prevention of aspiration pneumonia and/or sepsis
PL1698630T3 (pl) * 2005-03-03 2014-12-31 Alfasigma Spa Nowe postacie polimorficzne rifaksyminy,sposoby ich wytwarzania i ich zastosowanie w preparatach leczniczych
ITBO20050123A1 (it) 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
EP2069363B1 (fr) 2006-09-22 2013-03-20 Cipla Ltd. Rifaximine sous une forme amorphe
US20100136125A1 (en) 2006-12-28 2010-06-03 Jacobus Pharmaceutical Company, Inc. Method of treating inflammatory bowel disease
ITMI20071241A1 (it) 2007-06-20 2008-12-21 Solmag S P A Processo per la preparazione di rifaximina amorfa e rifaximina amorfa cosi' ottenuta
JP5755878B2 (ja) 2007-07-06 2015-07-29 ルパン リミテッドＬｕｐｉｎ Ｌｉｍｉｔｅｄ リファキシミンの薬剤組成物
US7709634B2 (en) * 2007-09-20 2010-05-04 Apotex Pharmachem Inc. Amorphous form of rifaximin and processes for its preparation
WO2009047801A1 (fr) 2007-10-10 2009-04-16 Lupin Limited Combinaisons thérapeutiques et compositions pour le traitement de troubles gastro-intestinaux
EP2257557A4 (fr) 2008-02-25 2011-06-29 Salix Pharmaceuticals Ltd Formes de rifaximine et utilisations correspondantes
US8486956B2 (en) 2008-02-25 2013-07-16 Salix Pharmaceuticals, Ltd Forms of rifaximin and uses thereof
WO2009137672A1 (fr) * 2008-05-07 2009-11-12 Salix Pharmaceuticals, Ltd. Procédés de traitement de maladie intestinale par l’administration d’un nettoyant d’intestin et d’un antibiotique
US20100209495A1 (en) 2008-09-17 2010-08-19 Mylan Laboratories, Inc. Granulates, process for preparing them and pharmaceutical products containing them
JP5756020B2 (ja) 2008-12-10 2015-07-29 シプラ・リミテッド リファキシミン複合体
KR20200100215A (ko) 2009-10-27 2020-08-25 루핀 리미티드 리팍시민의 고형 분산물
US8952159B2 (en) * 2009-12-28 2015-02-10 Silvio Massimo Lavagna Method for the production of amorphous rifaximin
EA022490B1 (ru) 2010-06-03 2016-01-29 Саликс Фармасьютикалс, Лтд. Новые формы рифаксимина и их применение
CA2802874A1 (fr) 2010-06-16 2011-12-22 Apotex Pharmachem Inc. Formes polymorphiques de rifaximine
KR20140026379A (ko) 2011-02-11 2014-03-05 샐릭스 파마슈티컬스 리미티드 리팍시민의 형태 및 이의 용도

Also Published As

Publication number Publication date
ZA201005961B (en) 2018-11-28
JP2011513243A (ja) 2011-04-28
SG10201607926VA (en) 2016-11-29
EP2257557A2 (fr) 2010-12-08
EA201370208A1 (ru) 2014-06-30
CN104650114A (zh) 2015-05-27
US8754098B2 (en) 2014-06-17
GEP20135898B (en) 2013-08-12
KR101674382B1 (ko) 2016-11-09
CR11657A (es) 2010-11-22
SG188931A1 (en) 2013-04-30
MX2010009389A (es) 2010-11-22
US20140011828A1 (en) 2014-01-09
MY158257A (en) 2016-09-30
WO2009108730A2 (fr) 2009-09-03
MX344737B (es) 2017-01-05
US9700545B2 (en) 2017-07-11
JP5706693B2 (ja) 2015-04-22
UA101829C2 (uk) 2013-05-13
IL207730A (en) 2016-04-21
CA2716830C (fr) 2019-01-08
UA113275C2 (xx) 2017-01-10
ZA201308527B (en) 2014-07-30
IL207730A0 (en) 2010-12-30
NZ587099A (en) 2012-08-31
JP2015129168A (ja) 2015-07-16
AU2009219342A1 (en) 2009-09-03
CR20150401A (es) 2015-11-19
US20160317507A1 (en) 2016-11-03
EA201001372A1 (ru) 2011-04-29
AU2009219342B2 (en) 2014-10-30
KR20100127797A (ko) 2010-12-06
US20150299199A1 (en) 2015-10-22
ME01032B (fr) 2012-10-20
CN102015725B (zh) 2014-10-22
US20110105550A1 (en) 2011-05-05
US20120076857A1 (en) 2012-03-29
US20100239664A1 (en) 2010-09-23
CA2716830A1 (fr) 2009-09-03
EA021176B1 (ru) 2015-04-30
CN102015725A (zh) 2011-04-13
US8067429B2 (en) 2011-11-29
US9359357B2 (en) 2016-06-07
US9181274B2 (en) 2015-11-10
WO2009108730A3 (fr) 2009-12-30
BRPI0908864A2 (pt) 2018-09-18
EP2257557A4 (fr) 2011-06-29
US20130066079A1 (en) 2013-03-14

Similar Documents

Publication Publication Date Title
MA32161B1 (fr) Formes de rifaximine et utilisations de celles-ci
EA201270722A1 (ru) Формы рифаксимина и их применение
EA201101521A1 (ru) Способы лечения онкологических заболеваний, использующие эпиметаболические переключатели, многоаспектные внутриклеточные молекулы или факторы влияния
EA201370018A1 (ru) Составы рифаксимина и их применение
EA201491009A1 (ru) Гель лизата тромбоцитов
EA201590343A1 (ru) Алкилпиримидиновые производные для лечения вирусных инфекций и дальнейших заболеваний
TW200716646A (en) (S)-N-methylnaltrexone
EA201170521A1 (ru) Новые соединения
EA200870193A1 (ru) Цитотоксические агенты, включающие новые производные томаймицина, и их терапевтическое применение
UA109464C2 (uk) Спірооксіндольні антагоністи mdm2
BR112012018345A2 (pt) "compostos de heteroarila, bem como composições e usos dos mesmos"
EA201391719A1 (ru) Хиназолиновые производные для лечения вирусных инфекций и дальнейших заболеваний
CR11731A (es) Composiciones y procedimientos para su preparación y uso
UY34350A (es) Derivados de pirazolquinolinona, su preparación y su uso terapéutico.
EA201170227A1 (ru) Имидазолкарбоксамиды
NZ702458A (en) Benzo [c] isoxazoloazepine bromodomain inhibitors and uses thereof
EA201190217A1 (ru) Замещенные 2-ацетамидо-5-арил-1,2,4-триазолоны и их применение
MX356400B (es) Moduladores novedosos y metodos de uso.
EA201070327A1 (ru) Катехоламиновые производные и их пролекарства
MA32544B1 (fr) Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique
EA201170753A1 (ru) Налмефена гидрохлорид дигидрат
EA201400771A1 (ru) Новые производные азетидина, фармацевтические композиции и их применение
EA201070009A1 (ru) Производные 7-алкинил-1,8-нафтиридонов, их получение и их применение в терапии
EA201391171A1 (ru) Формы рифаксимина и их применение
UA114417C2 (uk) Інгібітори iap